The story of the European Randomized Study of Screening for Prostate Cancer (Q35675436)

9 August 2017

1 reference

title

The story of the European Randomized Study of Screening for Prostate Cancer (English)

1 reference

9 August 2017

1 reference

5

A Auvinen

1 reference

9 August 2017

F H Schröder

1

1 reference

9 August 2017

L J Denis

2

1 reference

9 August 2017

M Roobol

3

1 reference

9 August 2017

V Nelen

4

1 reference

9 August 2017

T Tammela

6

1 reference

9 August 2017

A Villers

7

1 reference

9 August 2017

X Rebillard

8

1 reference

9 August 2017

S Ciatto

9

1 reference

9 August 2017

M Zappa

10

1 reference

9 August 2017

A Berenguer

11

1 reference

9 August 2017

A Paez

12

1 reference

9 August 2017

J Hugosson

13

1 reference

9 August 2017

P Lodding

14

1 reference

9 August 2017

F Recker

15

1 reference

9 August 2017

M Kwiatkowski

16

1 reference

9 August 2017

W J Kirkels

17

1 reference

9 August 2017

ERSPC

18

1 reference

9 August 2017

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

92 Suppl 2

1 reference

9 August 2017

1-13

1 reference

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland

9 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Ethics of a prostate cancer screening trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Why do men refuse or attend population-based screening for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Prostate cancer detection at low prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Final results of a screening campaign for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Three-year results of the Finnish prostate cancer screening trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

European randomized study of screening for prostate cancer--the Rotterdam pilot studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Should we start population screening for prostate cancer? Randomised trials are still needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

The European Randomized Study of Screening for Prostate Cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Lead-time in prostate cancer screening (Finland)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

PSA-use in a Spanish industrial area

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

Advanced prostate cancer: course, care, and cost implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.04389.X

10.1111/J.1464-410X.2003.04389.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference